據報人工智能初創xAI料至2029年收入逾130億美元
《彭博》引述消息報道,協助美國富豪馬斯克旗下人工智能初創xAI進行發債的摩根士丹利,上周四(5日)向願意認購最少5,000萬美元債券的投資者公開xAI賬簿部分資料,包括收入、盈利、現金流及預測。
報道指,xAI預計2029年年收入逾130億美元,今年底毛收益為10億美元。報道又指,xAI今年首季毛收入5,200萬美元,EBITDA虧損3.41億美元,2027年及2029年EBITDA將為27億及131億美元。現金流方面,在26億美元資本開支下,經營現金流負2.2億美元,未來將動用180億美元投資數據中心。
消息指有關數據未經核數師審核,會計準則或與上市公司採用的有差異。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.